Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Pyrantel

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Tablet Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 22, 2026, 10:07 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Image coming soon
Pyrantel

Pyrantel

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Tablet Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Pyrantel

For the removal and control of infections from the following mature parasites: Large strongyles ( Strongylus vulgaris , Strongylus edentatus , Strongylus equinus ), small strongyles, pinworms ( Oxyuris equi ) and large roundworms ( Parascaris ). For the removal and control of large roundworm ( Ascaris suum ) infections. Aid in the prevention of migration and establishment of large roundworm ( Ascaris suum ) infections; aid in the prevention of establishment of nodular worm ( Oesophagostomum ) infections. Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Dog, Restricted During Pregnancy.

Generic name
Pyrantel
Brand names
Dog Wormer Tablets, Dog Wormer Chewable Tablets D-Worm™ Adams™, Liqui-Vict 2X™, Evict®
Manufacturer
Multiple FDA sponsors
Species
Both, Dog, No Use Class Stated Or Implied, Dog, Restricted During Pregnancy, Horse, Not For Meat Production
Dosage forms
Tablet, Tablet (Chewable), Liquid (Suspension), Paste
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Dog Wormer Tablets Dog Wormer Chewable Tablets D-Worm™ Adams™ Liqui-Vict 2X™ Evict® Anthelban V Pyrantel Pamoate Suspension-2.27mg Pyrantel Pamoate Suspension-4.54mg Pyrantel Pamoate Suspension Pyrantel Pamoate Chewable Tablets Pyrantel Pamoate Paste Exodus™ Paste Exodus® Multi Dose Primex® Canine Primex® 2-X Primex™ Equine Primex® WormX® Strongid® 48 Continuex™
Dosage forms
Tablet Tablet (Chewable) Liquid (Suspension) Paste Flavored Tablets Top Dressing In Feed

Indications / Uses

For the removal and control of infections from the following mature parasites: Large strongyles ( Strongylus vulgaris , Strongylus edentatus , Strongylus equinus ), small strongyles, pinworms ( Oxyuris equi ) and large roundworms ( Parascaris ). For the removal and control of large roundworm ( Ascaris suum ) infections. Aid in the prevention of migration and establishment of large roundworm ( Ascaris suum ) infections; aid in the prevention of establishment of nodular worm ( Oesophagostomum ) infections.

Warnings / Contraindications

It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. Feed continuously as the sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.

  • It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. Feed continuously as the sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.

Side Effects

Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Lack of efficacy (endoparasite) - hookworm, INEFFECTIVE, HEARTWORM LARVAE, Diarrhoea, INEFFECTIVE, HOOKS.

FAQ

Both, Dog, No Use Class Stated Or Implied, Dog, Restricted During Pregnancy, Horse, Not For Meat Production, Pony, Not For Food, No Use Class Stated Or Implied, Dogs And Puppies, Horse, No Use Class Stated Or Implied, Pony, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Tablet, Tablet (Chewable), Liquid (Suspension), Paste

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

Prevention of Strongylus vulgaris larval infections; control of adult large strongyles ( S. vulgaris , S. edentates ); adult and 4th stage larvae small strongyles ( Cyathostomum species, Cylicocyclus species., Cylicostep...

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • It is recommended that severely debilitated animals not be treated with this drug
  • Do not use in horses intended for food
  • Feed for 3 days as sole ration in a Type C feed
  • Consult veterinarian before using in severely debilitated animals
  • Do not mix in Type B or Type C medicated feeds containing bentonite
  • Feed continuously as the sole ration in a Type C feed
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Hepatomegaly (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • It is recommended that severely debilitated animals not be treated with this drug
  • Do not use in horses intended for food
  • Feed for 3 days as sole ration in a Type C feed
  • Consult veterinarian before using in severely debilitated animals
  • Do not mix in Type B or Type C medicated feeds containing bentonite

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Hepatomegaly (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Flavored Tablets, Liquid (Suspension), Paste, Tablet, Tablet (Chewable), Top Dressing In Feed
Identifiers:
ANADA: 200007 ANADA: 200028 ANADA: 200246 ANADA: 200248 ANADA: 200281 ANADA: 200282 ANADA: 200338 ANADA: 200342 ANADA: 200350 ANADA: 200352 ANADA: 200353 ANADA: 200445 ANADA: 200600 NADA: 100237 NADA: 101331 NADA: 110047 NADA: 116044 NADA: 118814 NADA: 118815 NADA: 118874
Source metadata:

Warnings / Contraindications

It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. Feed continuously as the sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.

  • High: It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. Feed continuously as the sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
26
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Loss of appetite, Drooling Neurologic (2) · Unsteady walking (ataxia), Circling - neurological disorder Behavior (2) · Biting -aggression, Behavioral disorder (unspecified) Other (24) · Hepatomegaly, Heavy breathing, Gingivitis
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Digestive 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1

Species coverage: Cat (27) Dog (5)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Non-serious - 1
Neurologic Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Neurologic Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

21

FOI

45

Strongid® 48

SPL · SPL

Open original
FDA Structured Product Label

Strongid® 48

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
140-819
Status
OTC
Form
Top Dressing In Feed
Route
Oral
Species
Horse, Not For Meat Production
Composition / specifications
Type A medicated articles containing pyrantel tartrate 48 grams per pound.

Horses

Indication
Prevention of Strongylus vulgaris larval infections; control of adult large strongyles (S. vulgaris, S. edentates); adult and 4th stage larvae small strongyles (Cyathostomum species, Cylicocyclus species., Cylicostephanus species. Cylicodontophorus species, Poteriostomum species), Triodontophorus species; adult and 4th stage larvae pinworms (Oxyuris equi) and adult and 4th stage larvae ascarids (Parascaris equorum).
Dosage
1.2 milligrams per pound (2.64 milligrams per kilogram) of body weight.
Limitations

Administer either as a top-dress (not to exceed 20,000 grams per ton) or mixed in the horse's daily grain ration (not to exceed 1,200 grams per ton) during the time that the animal is at risk of exposure to internal parasites. Do not use in horses intended for human consumption. Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism. Do not mix in Type B or Type C medicated feeds containing bentonite.

Exodus™ Paste

SPL · SPL

Open original
FDA Structured Product Label

Exodus™ Paste Exodus® Multi Dose

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Bimeda Animal Health Limited
ANADA
200-350
Status
OTC
Form
Paste
Route
Oral
Species
No Use Class Stated Or Implied
Composition / specifications
Each milliliter of paste contains 171 milligrams of pyrantel base (as pyrantel pamoate).

Horses and ponies

Indication

For removal and control of infections from the following mature parasites: large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum).

Dosage

Administer as single dose by depositing paste on dorsum of the tongue using the dose syringe. Equivalent of 3 milligrams pyrantel base per pound of body weight.

Exodus® Multi Dose

SPL · SPL

Open original
FDA Structured Product Label

Exodus™ Paste Exodus® Multi Dose

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Bimeda Animal Health Limited
ANADA
200-350
Status
OTC
Form
Paste
Route
Oral
Species
No Use Class Stated Or Implied
Composition / specifications
Each milliliter of paste contains 171 milligrams of pyrantel base (as pyrantel pamoate).

Horses and ponies

Indication

For removal and control of infections from the following mature parasites: large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum).

Dosage

Administer as single dose by depositing paste on dorsum of the tongue using the dose syringe. Equivalent of 3 milligrams pyrantel base per pound of body weight.

WormX®

SPL · SPL

Open original
FDA Structured Product Label

WormX®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Sergeant’s Pet Care Products Inc.
ANADA
200-600
Status
OTC
Form
Flavored Tablets
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 mg or 113.5 mg pyrantel base

Label highlights

Indication

For removal of ascarids (Toxocara canis; Toxascaris leonina), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping

Dosage

22.7 mg tablet in puppies and small dogs

For the removal of large roundworms (Ascarids) and hookworms, give 1 tablet for each 10 lb of body weight. Dosage is designed to provide at least 2.27 mg per pound body weight for dogs weighing over 5 lb, and at least 4.54 mg per pound of body weight for dogs weighing 5 lb or less. For dogs weighing more than 10 lb, tablets may be broken in half to provide ½ tablet for each additional 5 lb of body weight.

113.5 mg tablet in large dogs

For the removal of large roundworms (Ascarids) and hookworms in adult dogs or young dogs weighing more than 25 lb, administer tablets according to the weight of the animal.

Limitations

Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examinations. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism

Pyrantel Pamoate Paste

SPL · SPL

Open original
FDA Structured Product Label

Pyrantel Pamoate Paste

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Farnam Companies, Inc.
ANADA
200-342
Status
OTC
Form
Paste
Route
Oral
Species
Horse, Not For Meat Production • Pony, Not For Food
Composition / specifications
Each milliliter of paste contains 226 milligrams of pyrantel base (as pyrantel pamoate).

Horses (and ponies)

Indication
For the removal and control of mature infections of tapeworms (Anoplocephala perfoliata).
Dosage
Equivalent of 6 milligrams pyrantel base per pound of body weight.
Limitations
Administer as single oral dose. Not for use in horses intended for food.
Indication
For removal and control of infections from the following mature parasites: large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum).
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight.
Limitations
Administer as single dose by depositing paste on dorsum of the tongue using the dose syringe. Not for use in horses intended for food. It is recommended that severely debilitated animals not be treated with this preparation. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Anthelban V

SPL · SPL

Open original
FDA Structured Product Label

Anthelban V

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Elanco US Inc.
ANADA
200-246
Status
RX/OTC
Form
Liquid (Suspension)
Route
Oral
Species
Horse, Not For Meat Production
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.

Horses (ponies)

Indication
For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris Strongylus edentatus, Strongylus equinus), small strongyles pinworms (Oxyuris), and large roundworms (Parascaris).
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight.
Limitations
Administered as a single dose mixed with the usual grain ration, or by stomach tube, or by dose syringe. Not for use in horses and ponies to be slaughtered for food purposes. When the drug is for administration by stomach tube, it shall be labeled: "Federal law restricts this drug to use by or on the order of a licensed veterinarian.” When the drug is not for administration by stomach tube, it shall be labeled: “Consult your veterinarian for in the diagnosis, control, and treatment of parasitism.”

Liqui-Vict 2X™

SPL · SPL

Open original
FDA Structured Product Label

Liqui-Vict 2X™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Happy Jack, Inc.
ANADA
200-007
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For the removal of large roundworms (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala)
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism

Dogs (puppies, adults, lactating bitches after whelping)

Indication
To prevent reinfections of Toxocara canis
Dosage
Equivalent to 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism

Pyrantel Pamoate Suspension-2.27mg

SPL · SPL

Open original
FDA Structured Product Label

Pyrantel Pamoate Suspension-2.27mg Pyrantel Pamoate Suspension-4.54mg Pyrantel Pamoate Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
ANADA
200-248
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For the removal of large roundworms (Toxocara canis and Toxascarias leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Dogs (puppies, adults, and in lactating bitches after whelping)

Indication
To prevent reinfections of Toxocara canis.
Dosage
Equivalent to 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

Pyrantel Pamoate Suspension-4.54mg

SPL · SPL

Open original
FDA Structured Product Label

Pyrantel Pamoate Suspension-2.27mg Pyrantel Pamoate Suspension-4.54mg Pyrantel Pamoate Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
ANADA
200-248
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For the removal of large roundworms (Toxocara canis and Toxascarias leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Dogs (puppies, adults, and in lactating bitches after whelping)

Indication
To prevent reinfections of Toxocara canis.
Dosage
Equivalent to 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

Pyrantel Pamoate Suspension

SPL · SPL

Open original
FDA Structured Product Label

Pyrantel Pamoate Suspension-2.27mg Pyrantel Pamoate Suspension-4.54mg Pyrantel Pamoate Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
ANADA
200-248
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For the removal of large roundworms (Toxocara canis and Toxascarias leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Dogs (puppies, adults, and in lactating bitches after whelping)

Indication
To prevent reinfections of Toxocara canis.
Dosage
Equivalent to 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

Dog Wormer Tablets

SPL · SPL

Open original
FDA Structured Product Label

Dog Wormer Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Farnam Companies, Inc.
NADA
101-331
Status
OTC
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7, 45.4, or 113.5 milligrams of pyrantel base.

Dogs

Indication
For removal and control of large roundworms (ascarids) (Toxocara canis and Toxascaris leonina), and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
For dogs weighing over 5 pounds, use at least 2.27 milligrams of pyrantel base per pound of body weight. For dogs weighing 5 pounds or less, use at least 4.54 milligrams of pyrantel base per pound of body weight.
Limitations
Administer orally directly or in a small amount of food. To prevent reinfection of T. canis in puppies, lactating bitches after whelping, and adult dogs; treat puppies 2, 3, 4, 6, 8, and 10 weeks of age; treat lactating bitches 2 to 3 weeks after whelping; routinely treat adult dogs monthly. Do not withhold food prior to or after treatment. The presence of these parasites should be confirmed by laboratory fecal examination. A followup fecal examination should be conducted 2 to 4 weeks after first treatment regimen to determine the need for re-treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Evict®

SPL · SPL

Open original
FDA Structured Product Label

Evict®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
ANADA
200-028
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Dog, Restricted During Pregnancy
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For removal of large roundworms (T. canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food.
Limitations
Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Dogs (adults, puppies, and lactating bitches)

Indication
To prevent reinfections of Toxocara canis.
Dosage
Equivalent to 2.27 or 4.54 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2,3,4,6,8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism. For use of 2.27 and 4.54 milligrams per milliliter product. See No. 023851 for use of 4.54 milligrams per milliliter product

Continuex™

SPL · SPL

Open original
FDA Structured Product Label

Continuex™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Farnam Companies, Inc.
ANADA
200-282
Status
OTC
Form
Top Dressing In Feed
Route
Oral
Species
Horse, Not For Meat Production
Composition / specifications
Type A medicated articles containing pyrantel tartrate 48 grams per pound.

Horses

Indication
Prevention of Strongylus vulgaris larval infections; control of adult large strongyles (S. vulgaris, S. edentatus); adult and 4th stage larvae small strongyles (Cyathostomum species, Cylicocyclus species., Cylicostephanus species, Cylicodontophorus species, Poteriostomum species); Triodontophorus species; adult and 4th stage larvae pinworms (Oxyuris equi) and adult and 4th stage larvae ascarids (Parascaris equorum).
Dosage
1.2 milligrams per pound (2.64 milligrams per kilogram) of body weight.
Limitations
Administer either as a top-dress (not to exceed 20,000 grams per ton) or mixed in the horse's daily grain ration (not to exceed 1,200 grams per ton) during the time that the animal is at risk of exposure to internal parasites. Not for use in horses intended for food. Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.

Dog Wormer Chewable Tablets

SPL · SPL

Open original
FDA Structured Product Label

Dog Wormer Chewable Tablets D-Worm™ Adams™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Farnam Companies, Inc.
NADA
139-191
Status
OTC
Form
Tablet (Chewable)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.

Dogs

Indication
For removal of ascarids (Toxocara canis; Toxascaris leonine), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping
Dosage
Provides at least 2.27 milligrams of pyrantel base per pound of body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examination. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

D-Worm™

SPL · SPL

Open original
FDA Structured Product Label

Dog Wormer Chewable Tablets D-Worm™ Adams™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Farnam Companies, Inc.
NADA
139-191
Status
OTC
Form
Tablet (Chewable)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.

Dogs

Indication
For removal of ascarids (Toxocara canis; Toxascaris leonine), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping
Dosage
Provides at least 2.27 milligrams of pyrantel base per pound of body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examination. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Adams™

SPL · SPL

Open original
FDA Structured Product Label

Dog Wormer Chewable Tablets D-Worm™ Adams™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Farnam Companies, Inc.
NADA
139-191
Status
OTC
Form
Tablet (Chewable)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.

Dogs

Indication
For removal of ascarids (Toxocara canis; Toxascaris leonine), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping
Dosage
Provides at least 2.27 milligrams of pyrantel base per pound of body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examination. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Primex®

SPL · SPL

Open original
FDA Structured Product Label

Primex®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
First Priority, Inc.
ANADA
200-445
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Horse, Not For Meat Production • Pony, Not For Food
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.

Horses and ponies

Indication
For the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); pinworms (Oxyuris equi); large roundworms (Parascaris equorum); and small strongyles.
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight
Limitations
Not for use in horses and ponies to be slaughtered for food purposes.

Primex® Canine

SPL · SPL

Open original
FDA Structured Product Label

Primex® Canine Primex® 2-X

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
First Priority, Inc.
ANADA
200-352
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dogs And Puppies
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For the removal of large roundworms (Toxocara canis and Toxascaris leonine) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Primex® 2-X

SPL · SPL

Open original
FDA Structured Product Label

Primex® Canine Primex® 2-X

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
First Priority, Inc.
ANADA
200-352
Status
OTC
Form
Liquid (Suspension)
Route
Oral
Species
Dogs And Puppies
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.

Dogs (and puppies)

Indication
For the removal of large roundworms (Toxocara canis and Toxascaris leonine) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Primex™ Equine

SPL · SPL

Open original
FDA Structured Product Label

Primex™ Equine

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
First Priority, Inc.
ANADA
200-353
Status
RX
Form
Liquid (Suspension)
Route
Oral
Species
Horse, No Use Class Stated Or Implied • Pony, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.

Horses (and ponies)

Indication
For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris Strongylus edentatus, Strongylus equinus), small strongyles pinworms (Oxyuris), and large roundworms (Parascaris).
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight.
Limitations
Administered as a single dose mixed with the usual grain ration, or by stomach tube, or by dose syringe. Not for use in horses and ponies to be slaughtered for food purposes. When the drug is for administration by stomach tube, it shall be labeled: "Federal law restricts this drug to use by or on the order of a licensed veterinarian.'' When the drug is not for administration by stomach tube, it shall be labeled: ``Consult your veterinarian for in the diagnosis, control, and treatment of parasitism.''

Pyrantel Pamoate Chewable Tablets

SPL · SPL

Open original
FDA Structured Product Label

Pyrantel Pamoate Chewable Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Virbac AH, Inc.
ANADA
200-281
Status
OTC
Form
Tablet (Chewable)
Route
Oral
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.

Dogs

Indication
For removal of ascarids (Toxocara canis; Toxascaris leonina), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping.
Dosage
Provides at least 2.27 milligrams of pyrantel base per pound of body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examination. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

ucm049948.pdf

FOI · FOI

Open original

N140819_Orig_04_18_1990.pdf

FOI · FOI

Open original

ucm061837.pdf

FOI · FOI

Open original

UCM488828.pdf

FOI · FOI

Open original

ucm061808.pdf

FOI · FOI

Open original

ucm061807.pdf

FOI · FOI

Open original

ucm061674.pdf

FOI · FOI

Open original

ucm061672.pdf

FOI · FOI

Open original

UCM351252.pdf

FOI · FOI

Open original

A200248_Orig_7_16_1998.pdf

FOI · FOI

Open original

UCM494205.pdf

FOI · FOI

Open original

N101331_Org_November_14_1978.pdf

FOI · FOI

Open original

A200028_Supp_6_4_1997.pdf

FOI · FOI

Open original

UCM323297.pdf

FOI · FOI

Open original

ucm061708.pdf

FOI · FOI

Open original

UCM508348.pdf

FOI · FOI

Open original

ucm061374.pdf

FOI · FOI

Open original

ucm059255.pdf

FOI · FOI

Open original

ucm059258.pdf

FOI · FOI

Open original

ucm061707.pdf

FOI · FOI

Open original

FOI Summary oN 141-581 Approved October 7, 2024.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-581 Approved May 21, 2025.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-581 Approved October 20, 2025.pdf

FOI · FOI summary

Open original

FOI Summary oN 141-554 Approved July 19, 2023.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-554 Approved October 7, 2024.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-554 Approved April 23 2025_EF.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-554 Approved January 20, 2026.pdf

FOI · FOI summary

Open original

FOI Summary o 141-619 Approved December 17, 2025 (2).pdf

FOI · FOI summary

Open original

UCM539434.pdf

FOI · FOI summary

Open original

FOI Summary oN 141-521 Approved February 27, 2020.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-521 Approved December 23, 2021.sum.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-521 Approved November 6, 2024.pdf

FOI · FOI summary

Open original

FOI Summary sN 141-521 Approved April 8 2025_ceg_ef.pdf

FOI · FOI summary

Open original

ucm061802.pdf

FOI · FOI summary

Open original

UCM050062.pdf

FOI · FOI summary

Open original

N141007_Orig_5_19_1994.pdf

FOI · FOI summary

Open original

N141007_Supp_03-28-1996.pdf

FOI · FOI summary

Open original

ucm116050.pdf

FOI · FOI summary

Open original

ucm116081.pdf

FOI · FOI summary

Open original

UCM487815.pdf

FOI · FOI summary

Open original

FOI Summary oN 141-441 Approved December 11, 2017.pdf

FOI · FOI summary

Open original

UCM051416.pdf

FOI · FOI summary

Open original

ucm051414.pdf

FOI · FOI summary

Open original

UCM487710.pdf

FOI · FOI summary

Open original

UCM487711.pdf

FOI · FOI summary

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog, Dogs And Puppies, Horse, No Use Class Stated Or Implied, Pony
Rx/OTC: OTC, RX, RX/OTC
Form/route: Flavored Tablets, Liquid (Suspension), Paste, Tablet, Tablet (Chewable), Top Dressing In Feed • Oral
Applications: NADA 140-819 • ANADA 200-350 • ANADA 200-600 • ANADA 200-342 • ANADA 200-246 • ANADA 200-007 • ANADA 200-248 • NADA 101-331 • ANADA 200-028 • ANADA 200-282 • NADA 139-191 • ANADA 200-445 • ANADA 200-352 • ANADA 200-353 • ANADA 200-281
Documents: 20 (FOI: 20) • SPL: 21 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 17 • Cat 44 • View
Case summaries: 9 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Diagnosis Codes
ICD10_CM: B74.8 ICD10_CM: B88.1
Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. Feed continuously as the sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Hepatomegaly (1) Gingivitis (1) Fracture (1) Fibrosarcoma (1) Elevated globulins (1) Elevated creatinine (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200007 ANADA: 200028 ANADA: 200246 ANADA: 200248 ANADA: 200281 ANADA: 200282 ANADA: 200338 ANADA: 200342 ANADA: 200350 ANADA: 200352 ANADA: 200353 ANADA: 200445 ANADA: 200600 NADA: 100237 NADA: 101331 NADA: 110047 NADA: 116044 NADA: 118814 NADA: 118815 NADA: 118874 NADA: 118875 NADA: 118877 NADA: 119062 NADA: 119063
Package NDC Product NDC Form / Route Status
0010-4012-01 0010 -
0010-4012-02 0010 -
0010-4012-03 0010 -
0010-4012-04 0010 -
0010-4013-01 0010 -
0010-4013-02 0010 -
0010-4013-03 0010 -
0010-4013-04 0010 -
0010-4014-01 0010 -
0010-4014-02 0010 -
0010-4014-03 0010 -
0010-4014-04 0010 -
0010-4260-01 0010 -
0010-4260-02 0010 -
0010-4260-03 0010 -
0010-4261-01 0010 -
0010-4261-02 0010 -
0010-4261-03 0010 -
0010-4262-01 0010 -
0010-4262-02 0010 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 64 Clinical 9 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a … (Clinical, 2026-04-15)
  • contraindications: It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a … (Clinical, 2026-04-15)
  • contraindications: It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a … (Clinical, 2026-04-11)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Lack of efficacy (endoparasite) - hookworm, INEFFECTIVE, HEARTWORM LAR… (Clinical, 2026-04-11)
  • usage: For the removal and control of infections from the following mature parasites: Large strongyles ( Strongylus vulgaris , Strongylus edentatus , Strongylus equin… (Clinical, 2026-04-15)
  • usage: For the removal and control of infections from the following mature parasites: Large strongyles ( Strongylus vulgaris , Strongylus edentatus , Strongylus equin… (Clinical, 2026-04-15)
  • usage: For the removal and control of infections from the following mature parasites: Large strongyles ( Strongylus vulgaris , Strongylus edentatus , Strongylus equin… (Clinical, 2026-04-11)
  • contraindications: It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a … (Official, 2026-04-22)
  • contraindications: It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a … (Official, 2026-02-12)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-05-05)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-05-03)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-05-02)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-04-29)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-04-28)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-04-27)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-04-26)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-04-25)
  • indications: For the prevention of Strongylus vulgaris larval infections in horses. For control of the following parasites in horses: Large Strongyles (adults) S. vulgaris,… (Official, 2026-04-22)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-16 13:27 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 13:27 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 13:27 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 13:27 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 13:27 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 13:27 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-15 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-15 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-15 10:06 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-15 10:06 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-15 10:06 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-15 10:06 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Strongid® 48
OTC
Pyrantel Tartrate
Top Dressing In Feed • Oral
Label highlights
Official documents
Zoetis Inc. NADA 140-819 Approved Nov 7, 2023
Exodus™ Paste Exodus® Multi Dose
OTC
Pyrantel Pamoate
Paste • Oral
Label highlights
Official documents
Bimeda Animal Health Limited ANADA 200-350 Approved May 29, 2020
WormX®
OTC
Pyrantel Pamoate
Flavored Tablets • Oral
Label highlights
Official documents
Sergeant’s Pet Care Products Inc. ANADA 200-600 W Apr 1, 2019
Pyrantel Pamoate Paste
OTC
Pyrantel Pamoate
Paste • Oral
Label highlights
Official documents
Farnam Companies, Inc. ANADA 200-342 Approved Dec 27, 2017
Anthelban V
RX/OTC
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
Elanco US Inc. ANADA 200-246 Approved Dec 19, 2017
Liqui-Vict 2X™
OTC
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
Happy Jack, Inc. ANADA 200-007 Approved Dec 19, 2017
Pyrantel Pamoate Suspension-2.27mg Pyrantel Pamoate Suspension-4.54mg Pyrantel Pamoate Suspension
OTC
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. ANADA 200-248 Approved Jul 19, 2017
Dog Wormer Tablets
OTC
Pyrantel Pamoate
Tablet • Oral
Label highlights
Official documents
Farnam Companies, Inc. NADA 101-331 Approved Jul 12, 2017
Evict®
OTC
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
Pegasus Laboratories, Inc. ANADA 200-028 W Jul 11, 2017
Continuex™
OTC
Pyrantel Tartrate
Top Dressing In Feed • Oral
Label highlights
Official documents
Farnam Companies, Inc. ANADA 200-282 Approved Jun 1, 2016
Dog Wormer Chewable Tablets D-Worm™ Adams™
OTC
Pyrantel Pamoate
Tablet (Chewable) • Oral
Label highlights
Official documents
Farnam Companies, Inc. NADA 139-191 Approved Jun 1, 2016
Primex®
OTC
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
First Priority, Inc. ANADA 200-445 Approved Jun 1, 2016
Primex® Canine Primex® 2-X
OTC
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
First Priority, Inc. ANADA 200-352 Approved Jun 1, 2016
Primex™ Equine
RX
Pyrantel Pamoate
Liquid (Suspension) • Oral
Label highlights
Official documents
First Priority, Inc. ANADA 200-353 Approved Jun 1, 2016
Pyrantel Pamoate Chewable Tablets
OTC
Pyrantel Pamoate
Tablet (Chewable) • Oral
Label highlights
Official documents
Virbac AH, Inc. ANADA 200-281 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Horse, Not For Meat Production
Composition / specifications
Type A medicated articles containing pyrantel tartrate 48 grams per pound.
Horses
Indication
Prevention of Strongylus vulgaris larval infections; control of adult large strongyles (S. vulgaris, S. edentates); adult and 4th stage larvae small strongyles (Cyathostomum species, Cylicocyclus species., Cylicostephanus species. Cylicodontophorus species, Poteriostomum species), Triodontophorus species; adult and 4th stage larvae pinworms (Oxyuris equi) and adult and 4th stage larvae ascarids (Parascaris equorum).
Dosage
1.2 milligrams per pound (2.64 milligrams per kilogram) of body weight.
Limitations

Administer either as a top-dress (not to exceed 20,000 grams per ton) or mixed in the horse's daily grain ration (not to exceed 1,200 grams per ton) during the time that the animal is at risk of exposure to internal parasites. Do not use in horses intended for human consumption. Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism. Do not mix in Type B or Type C medicated feeds containing bentonite.

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied
Composition / specifications
Each milliliter of paste contains 171 milligrams of pyrantel base (as pyrantel pamoate).
Horses and ponies
Indication

For removal and control of infections from the following mature parasites: large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum).

Dosage

Administer as single dose by depositing paste on dorsum of the tongue using the dose syringe. Equivalent of 3 milligrams pyrantel base per pound of body weight.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 mg or 113.5 mg pyrantel base
Label highlights
Indication

For removal of ascarids (Toxocara canis; Toxascaris leonina), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping

Dosage

22.7 mg tablet in puppies and small dogs

For the removal of large roundworms (Ascarids) and hookworms, give 1 tablet for each 10 lb of body weight. Dosage is designed to provide at least 2.27 mg per pound body weight for dogs weighing over 5 lb, and at least 4.54 mg per pound of body weight for dogs weighing 5 lb or less. For dogs weighing more than 10 lb, tablets may be broken in half to provide ½ tablet for each additional 5 lb of body weight.

113.5 mg tablet in large dogs

For the removal of large roundworms (Ascarids) and hookworms in adult dogs or young dogs weighing more than 25 lb, administer tablets according to the weight of the animal.

Limitations

Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examinations. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production • Pony, Not For Food
Composition / specifications
Each milliliter of paste contains 226 milligrams of pyrantel base (as pyrantel pamoate).
Horses (and ponies)
Indication
For the removal and control of mature infections of tapeworms (Anoplocephala perfoliata).
Dosage
Equivalent of 6 milligrams pyrantel base per pound of body weight.
Limitations
Administer as single oral dose. Not for use in horses intended for food.
Indication
For removal and control of infections from the following mature parasites: large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum).
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight.
Limitations
Administer as single dose by depositing paste on dorsum of the tongue using the dose syringe. Not for use in horses intended for food. It is recommended that severely debilitated animals not be treated with this preparation. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.
Horses (ponies)
Indication
For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris Strongylus edentatus, Strongylus equinus), small strongyles pinworms (Oxyuris), and large roundworms (Parascaris).
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight.
Limitations
Administered as a single dose mixed with the usual grain ration, or by stomach tube, or by dose syringe. Not for use in horses and ponies to be slaughtered for food purposes. When the drug is for administration by stomach tube, it shall be labeled: "Federal law restricts this drug to use by or on the order of a licensed veterinarian.” When the drug is not for administration by stomach tube, it shall be labeled: “Consult your veterinarian for in the diagnosis, control, and treatment of parasitism.”

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 4.54 milligrams of pyrantel base per milliliter.
Dogs (and puppies)
Indication
For the removal of large roundworms (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala)
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism
Dogs (puppies, adults, lactating bitches after whelping)
Indication
To prevent reinfections of Toxocara canis
Dosage
Equivalent to 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.
Dogs (and puppies)
Indication
For the removal of large roundworms (Toxocara canis and Toxascarias leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
Dogs (puppies, adults, and in lactating bitches after whelping)
Indication
To prevent reinfections of Toxocara canis.
Dosage
Equivalent to 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7, 45.4, or 113.5 milligrams of pyrantel base.
Dogs
Indication
For removal and control of large roundworms (ascarids) (Toxocara canis and Toxascaris leonina), and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
For dogs weighing over 5 pounds, use at least 2.27 milligrams of pyrantel base per pound of body weight. For dogs weighing 5 pounds or less, use at least 4.54 milligrams of pyrantel base per pound of body weight.
Limitations
Administer orally directly or in a small amount of food. To prevent reinfection of T. canis in puppies, lactating bitches after whelping, and adult dogs; treat puppies 2, 3, 4, 6, 8, and 10 weeks of age; treat lactating bitches 2 to 3 weeks after whelping; routinely treat adult dogs monthly. Do not withhold food prior to or after treatment. The presence of these parasites should be confirmed by laboratory fecal examination. A followup fecal examination should be conducted 2 to 4 weeks after first treatment regimen to determine the need for re-treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Dog, Restricted During Pregnancy
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.
Dogs (and puppies)
Indication
For removal of large roundworms (T. canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food.
Limitations
Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
Dogs (adults, puppies, and lactating bitches)
Indication
To prevent reinfections of Toxocara canis.
Dosage
Equivalent to 2.27 or 4.54 milligrams of pyrantel base per pound of body weight.
Limitations
Administer to puppies at 2,3,4,6,8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism. For use of 2.27 and 4.54 milligrams per milliliter product. See No. 023851 for use of 4.54 milligrams per milliliter product

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production
Composition / specifications
Type A medicated articles containing pyrantel tartrate 48 grams per pound.
Horses
Indication
Prevention of Strongylus vulgaris larval infections; control of adult large strongyles (S. vulgaris, S. edentatus); adult and 4th stage larvae small strongyles (Cyathostomum species, Cylicocyclus species., Cylicostephanus species, Cylicodontophorus species, Poteriostomum species); Triodontophorus species; adult and 4th stage larvae pinworms (Oxyuris equi) and adult and 4th stage larvae ascarids (Parascaris equorum).
Dosage
1.2 milligrams per pound (2.64 milligrams per kilogram) of body weight.
Limitations
Administer either as a top-dress (not to exceed 20,000 grams per ton) or mixed in the horse's daily grain ration (not to exceed 1,200 grams per ton) during the time that the animal is at risk of exposure to internal parasites. Not for use in horses intended for food. Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.
Dogs
Indication
For removal of ascarids (Toxocara canis; Toxascaris leonine), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping
Dosage
Provides at least 2.27 milligrams of pyrantel base per pound of body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examination. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production • Pony, Not For Food
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.
Horses and ponies
Indication
For the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); pinworms (Oxyuris equi); large roundworms (Parascaris equorum); and small strongyles.
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight
Limitations
Not for use in horses and ponies to be slaughtered for food purposes.

FDA page: Open in Animal Drugs @ FDA

Species: Dogs And Puppies
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 2.27 or 4.54 milligrams of pyrantel base per milliliter.
Dogs (and puppies)
Indication
For the removal of large roundworms (Toxocara canis and Toxascaris leonine) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).
Dosage
Equivalent of 2.27 milligrams of pyrantel base per pound of body weight.
Limitations
Administer in the animal's feed bowl as a single dose by itself or mixed in a small quantity of food. Additional treatment may be required and should be confirmed by examination within 2 to 4 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, No Use Class Stated Or Implied • Pony, No Use Class Stated Or Implied
Composition / specifications
Pyrantel pamoate suspension contains pyrantel pamoate equivalent to 50 milligrams of pyrantel base per milliliter.
Horses (and ponies)
Indication
For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris Strongylus edentatus, Strongylus equinus), small strongyles pinworms (Oxyuris), and large roundworms (Parascaris).
Dosage
Equivalent of 3 milligrams pyrantel base per pound of body weight.
Limitations
Administered as a single dose mixed with the usual grain ration, or by stomach tube, or by dose syringe. Not for use in horses and ponies to be slaughtered for food purposes. When the drug is for administration by stomach tube, it shall be labeled: "Federal law restricts this drug to use by or on the order of a licensed veterinarian.'' When the drug is not for administration by stomach tube, it shall be labeled: ``Consult your veterinarian for in the diagnosis, control, and treatment of parasitism.''

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.
Dogs
Indication
For removal of ascarids (Toxocara canis; Toxascaris leonina), and hookworms (Ancylostoma caninum; Uncinaria stenocephala) in dogs and puppies. To prevent reinfection of Toxocara canis in puppies and adult dogs and in lactating bitches after whelping.
Dosage
Provides at least 2.27 milligrams of pyrantel base per pound of body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less.
Limitations
Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Retreatment of adult dogs may be necessary at monthly intervals as determined by laboratory fecal examination. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

FDA page: Open in Animal Drugs @ FDA

Usage

For the removal and control of infections from the following mature parasites: Large strongyles ( Strongylus vulgaris , Strongylus edentatus , Strongylus equinus ), small strongyles, pinworms ( Oxyuris equi ) and large roundworms ( Parascaris ). For the removal and control of large roundworm ( Ascaris suum ) infections. Aid in the prevention of migration and establishment of large roundworm ( Ascaris suum ) infections; aid in the prevention of establishment of nodular worm ( Oesophagostomum ) infections.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

It is recommended that severely debilitated animals not be treated with this drug. Do not use in horses intended for food. Feed for 3 days as sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite. Feed continuously as the sole ration in a Type C feed. Consult veterinarian before using in severely debilitated animals. Do not mix in Type B or Type C medicated feeds containing bentonite.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Loss of appetite (1) • Cat Drooling (1) • Cat Diarrhea (1) • Cat

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Cat Circling - neurological disorder (1) • Cat

Showing top 5 for Neurologic.

Behavior
Biting -aggression (1) • Cat Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Hepatomegaly (1) • Cat Heavy breathing (1) • Cat Gingivitis (1) • Cat Fracture (1) • Dog Fibrosarcoma (1) • Cat
Show more (19)
Fever (1) • Cat Elevated globulins (1) • Cat Elevated creatinine (1) • Cat Dilated pupils (1) • Cat Dehydration (1) • Cat Decreased activity (1) • Cat Death (1) • Dog Conjunctivitis (1) • Dog Confusion (1) • Cat Cardiomyopathy (1) • Cat Cachexia (1) • Cat Bradycardia (1) • Cat Anaphylaxis (1) • Cat Allergy NOS (1) • Dog Administration error NOS (1) • Cat Accidental exposure (1) • Cat Abnormal radiograph finding (1) • Cat Abnormal histology NOS (1) • Cat Abnormal cytology (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Terrier - Irish Soft-coated Wheaten, Male, 12 year, 21.319 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074219
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 21.319 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Death
Outcomes: Died

Dog, ['Bulldog - American', 'Dog (unknown)'], Male, 9 year, 27.941 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Unwell, Recumbency, Reduced responses, Seizure NOS, Stroke… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-072925
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 27.941 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Unwell Recumbency Reduced responses Seizure NOS Stroke Death Overdose
Outcomes: Died

Cat, Domestic Shorthair, Male, 13 week, 2.3 kilogram • Drug: MSK, Oral • Reactions: Injection site pain, Injection site reaction NOS, Vocalisation, Limb non-weight bearing, Diarrhea… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-073476
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 13.00 Week
  • Weight: 2.300 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Injection site pain Injection site reaction NOS Vocalisation Limb non-weight bearing Diarrhea Vomiting Tiredness (lethargy)
Outcomes: Ongoing

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Female, 11 month • Drug: MSK, Unknown • Reactions: Fracture, Thrombocytopenia, Respiratory tract infection NOS, Conjunctivitis, Unclassifiable adverse event… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-068774
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Month
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Fracture Thrombocytopenia Respiratory tract infection NOS Conjunctivitis Unclassifiable adverse event Other abnormal test result NOS Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Cat, Domestic Mediumhair, Female, 6.08 year, 4.82 kilogram • Drug: MSK, Unknown • Reactions: Fibrosarcoma, Decreased activity, Hissing, Injection site lump, Behavioral disorder (unspecified)… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-070682
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 6.08 Year
  • Weight: 4.820 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Fibrosarcoma Decreased activity Hissing Injection site lump Behavioral disorder (unspecified) Tooth disorder Gingivitis Neoplasia NOS Leucocytosis NOS Skin inflammation NOS Abnormal radiograph finding Abnormal cytology
Outcomes: Outcome Unknown

Dog, Shepherd Dog - Australian, Female, 3 month • Drug: MSK, Unknown • Reactions: Lack of efficacy (endoparasite) - hookworm, Diarrhea, Vomiting • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-069347
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 3.00 Month
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Lack of efficacy (endoparasite) - hookworm Diarrhea Vomiting
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 2 month, 0.52 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Hepatomegaly, Abnormal radiograph finding, Hypothermia, Weight loss, Sickness… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-069852
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 2.00 Month
  • Weight: 0.520 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Hepatomegaly Abnormal radiograph finding Hypothermia Weight loss Sickness Vomiting
Outcomes: Ongoing

Cat, Domestic Mediumhair, Male, 10 week, 1.179 kilogram • Drug: MSK, Oral • Reactions: Weight loss, Not eating, Vomiting, Tiredness (lethargy), Dehydration… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-067132
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Week
  • Weight: 1.179 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Weight loss Not eating Vomiting Tiredness (lethargy) Dehydration Hyperglycaemia Elevated creatinine Hyperproteinaemia Hyperalbuminaemia Elevated globulins Death Bradycardia Cardiomyopathy Muscle wasting Increased respiratory rate Hypothermia Cachexia Lateral recumbency Laboured breathing Necropsy performed Renal tubular disorder Abnormal histology NOS
Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.